Angiogenesis and gastrointestinal cancer

Ellen Kossoff, Wen Wee Ma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Angiogenesis is now a proven therapeutic cancer target. Approaches targeting the vascular endothelial growth factor and receptor (VEGF/VEGFR) axis have yielded success in gastrointestinal cancers. Bevacizumab is a humanized recombinant monoclonal antibody against VEGF and is the first antiangiogenic drug to enter clinical practice. Bevacizumab was approved for the treatment of advanced colorectal cancer by US FDA in 2004 in combination with fluorouracilbased chemotherapy. Hepatocellular carcinoma (HCC) is the next gastrointestinal cancer where angiogenesis proved to be of therapeutic importance. Sorafenib is a multi-kinase inhibitor of VEGFRs and Raf protein, and demonstrated anticancer effects in a subgroup of HCC patients. There are currently a number of antiangiogenic agents targeting the VEGF/VEGFR axis, which can be broadly categorized as monoclonal antibodies and tyrosine kinase inhibitors. These agents are being evaluated in a number of gastrointestinal cancers.

Original languageEnglish (US)
Title of host publicationAngiogenesis & Therapeutic Targets In Cancer
PublisherBentham Science Publishers Ltd.
Pages18-30
Number of pages13
ISBN (Print)9781608055739
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Gastrointestinal Neoplasms
Vascular Endothelial Growth Factor A
Hepatocellular Carcinoma
Phosphatidylethanolamine Binding Protein
Antibodies, Monoclonal, Humanized
Vascular Endothelial Growth Factor Receptor
Angiogenesis Inhibitors
Protein-Tyrosine Kinases
Colorectal Neoplasms
Therapeutics
Monoclonal Antibodies
Drug Therapy
Pharmaceutical Preparations
Neoplasms
Bevacizumab

Keywords

  • Angiogenesis
  • Gastrointestinal cancer
  • Monoclonal antibodies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kossoff, E., & Ma, W. W. (2010). Angiogenesis and gastrointestinal cancer. In Angiogenesis & Therapeutic Targets In Cancer (pp. 18-30). Bentham Science Publishers Ltd.. https://doi.org/10.2174/978160805007911001010018

Angiogenesis and gastrointestinal cancer. / Kossoff, Ellen; Ma, Wen Wee.

Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd., 2010. p. 18-30.

Research output: Chapter in Book/Report/Conference proceedingChapter

Kossoff, E & Ma, WW 2010, Angiogenesis and gastrointestinal cancer. in Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd., pp. 18-30. https://doi.org/10.2174/978160805007911001010018
Kossoff E, Ma WW. Angiogenesis and gastrointestinal cancer. In Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd. 2010. p. 18-30 https://doi.org/10.2174/978160805007911001010018
Kossoff, Ellen ; Ma, Wen Wee. / Angiogenesis and gastrointestinal cancer. Angiogenesis & Therapeutic Targets In Cancer. Bentham Science Publishers Ltd., 2010. pp. 18-30
@inbook{5b06ac96b7c44c11af55015ae8b714d9,
title = "Angiogenesis and gastrointestinal cancer",
abstract = "Angiogenesis is now a proven therapeutic cancer target. Approaches targeting the vascular endothelial growth factor and receptor (VEGF/VEGFR) axis have yielded success in gastrointestinal cancers. Bevacizumab is a humanized recombinant monoclonal antibody against VEGF and is the first antiangiogenic drug to enter clinical practice. Bevacizumab was approved for the treatment of advanced colorectal cancer by US FDA in 2004 in combination with fluorouracilbased chemotherapy. Hepatocellular carcinoma (HCC) is the next gastrointestinal cancer where angiogenesis proved to be of therapeutic importance. Sorafenib is a multi-kinase inhibitor of VEGFRs and Raf protein, and demonstrated anticancer effects in a subgroup of HCC patients. There are currently a number of antiangiogenic agents targeting the VEGF/VEGFR axis, which can be broadly categorized as monoclonal antibodies and tyrosine kinase inhibitors. These agents are being evaluated in a number of gastrointestinal cancers.",
keywords = "Angiogenesis, Gastrointestinal cancer, Monoclonal antibodies, Tyrosine kinase inhibitors",
author = "Ellen Kossoff and Ma, {Wen Wee}",
year = "2010",
month = "12",
day = "1",
doi = "10.2174/978160805007911001010018",
language = "English (US)",
isbn = "9781608055739",
pages = "18--30",
booktitle = "Angiogenesis & Therapeutic Targets In Cancer",
publisher = "Bentham Science Publishers Ltd.",

}

TY - CHAP

T1 - Angiogenesis and gastrointestinal cancer

AU - Kossoff, Ellen

AU - Ma, Wen Wee

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Angiogenesis is now a proven therapeutic cancer target. Approaches targeting the vascular endothelial growth factor and receptor (VEGF/VEGFR) axis have yielded success in gastrointestinal cancers. Bevacizumab is a humanized recombinant monoclonal antibody against VEGF and is the first antiangiogenic drug to enter clinical practice. Bevacizumab was approved for the treatment of advanced colorectal cancer by US FDA in 2004 in combination with fluorouracilbased chemotherapy. Hepatocellular carcinoma (HCC) is the next gastrointestinal cancer where angiogenesis proved to be of therapeutic importance. Sorafenib is a multi-kinase inhibitor of VEGFRs and Raf protein, and demonstrated anticancer effects in a subgroup of HCC patients. There are currently a number of antiangiogenic agents targeting the VEGF/VEGFR axis, which can be broadly categorized as monoclonal antibodies and tyrosine kinase inhibitors. These agents are being evaluated in a number of gastrointestinal cancers.

AB - Angiogenesis is now a proven therapeutic cancer target. Approaches targeting the vascular endothelial growth factor and receptor (VEGF/VEGFR) axis have yielded success in gastrointestinal cancers. Bevacizumab is a humanized recombinant monoclonal antibody against VEGF and is the first antiangiogenic drug to enter clinical practice. Bevacizumab was approved for the treatment of advanced colorectal cancer by US FDA in 2004 in combination with fluorouracilbased chemotherapy. Hepatocellular carcinoma (HCC) is the next gastrointestinal cancer where angiogenesis proved to be of therapeutic importance. Sorafenib is a multi-kinase inhibitor of VEGFRs and Raf protein, and demonstrated anticancer effects in a subgroup of HCC patients. There are currently a number of antiangiogenic agents targeting the VEGF/VEGFR axis, which can be broadly categorized as monoclonal antibodies and tyrosine kinase inhibitors. These agents are being evaluated in a number of gastrointestinal cancers.

KW - Angiogenesis

KW - Gastrointestinal cancer

KW - Monoclonal antibodies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84884460213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884460213&partnerID=8YFLogxK

U2 - 10.2174/978160805007911001010018

DO - 10.2174/978160805007911001010018

M3 - Chapter

AN - SCOPUS:84884460213

SN - 9781608055739

SP - 18

EP - 30

BT - Angiogenesis & Therapeutic Targets In Cancer

PB - Bentham Science Publishers Ltd.

ER -